Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information about where the ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and minimal ...

Meanwhile, the company said that 85% of GLP-1 subscribers continue to take their prescriptions four weeks after it is first prescribed and that 70% remain on it at 12 weeks. Hims & Hers ramped up ...